Literature DB >> 15961528

Increased corpus cavernosum smooth muscle tone associated with partial bladder outlet obstruction is mediated via Rho-kinase.

Shaohua Chang1, Joseph A Hypolite, Stephen A Zderic, Alan J Wein, Samuel Chacko, Michael E Disanto.   

Abstract

Numerous studies have now demonstrated that lower urinary tract symptoms (LUTS) are associated with erectile dysfunction (ED) in men independent of age or general health. Because one-third of men over the age of 50 will develop LUTS and a recent study showed ED in 62% of patients presenting for LUTS, the importance of determining the mechanistic link between these two pathologies is clear. Using a rabbit model of partial bladder outlet obstruction (PBOO), a primary cause of LUTS, we have identified an increased basal corpus cavernosum smooth muscle (CCSM) tone associated with an elevated level of smooth muscle myosin (SMM) phosphorylation in PBOO compared with sham-operated control rabbits (sham). Results from in vitro kinase and phosphatase assays using purified smooth muscle myosin showed increased kinase and decreased phosphatase activities in cellular extracts from corpora cavernosa isolated from PBOO compared with sham rabbits. Increased Rho-kinase expression in the CCSM of PBOO rabbits was suggested by the observations that Rho-kinase inhibitors attenuated the increased kinase activity and were less effective in relaxing CCSM strips from PBOO vs. sham rabbits. This hypothesis was then confirmed by RT-PCR and Western blotting, which demonstrated increased expression of both isoforms of Rho-kinase (ROKalpha and ROKbeta). Increased SMM basal phosphorylation (necessary for SM contraction) in the CCSM of PBOO rabbits, mediated via an increase in Rho-kinase expression/activity, would be expected to make the CCSM more difficult to relax (necessary for erection), which suggests that the RhoA/Rho-kinase pathway as being involved in the mechanism for LUTS-associated ED.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15961528     DOI: 10.1152/ajpregu.00717.2003

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  8 in total

1.  Current Diagnosis and Management of Erectile Dysfunction.

Authors:  Alexander W Pastuszak
Journal:  Curr Sex Health Rep       Date:  2014-09

2.  Phosphodiesterase type 5 inhibitors for the treatment of male lower urinary tract symptoms.

Authors:  Steven A Kaplan; Ricardo R Gonzalez
Journal:  Rev Urol       Date:  2007

3.  Urodynamic effects of once-daily tadalafil in men with LUTS secondary to clinical BPH.

Authors:  Alex Gomelsky; Roger R Dmochowski
Journal:  Curr Urol Rep       Date:  2010-07       Impact factor: 3.092

4.  Pathogenic mechanisms linking benign prostatic hyperplasia, lower urinary tract symptoms and erectile dysfunction.

Authors:  Sidney Glina; Felipe Placco Araujo Glina
Journal:  Ther Adv Urol       Date:  2013-08

5.  Up-regulation of the RhoA/Rho-kinase signaling pathway in corpus cavernosum from endothelial nitric-oxide synthase (NOS), but not neuronal NOS, null mice.

Authors:  Fernanda B M Priviero; Li-Ming Jin; Zhekang Ying; Cleber E Teixeira; R Clinton Webb
Journal:  J Pharmacol Exp Ther       Date:  2010-01-21       Impact factor: 4.030

Review 6.  Guide to drug therapy for lower urinary tract symptoms in patients with benign prostatic obstruction : implications for sexual dysfunction.

Authors:  Serap Gur; Philip J Kadowitz; Wayne J G Hellstrom
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  Correlation of Subjective Symptoms in Patients with Benign Prostatic Hyperplasia and Erectile Dysfunction.

Authors:  Amel Kardasevic; Snjezana Milicevic
Journal:  Med Arch       Date:  2017-02-05

8.  Corneal Endothelial Cell Migration and Proliferation Enhanced by Rho Kinase (ROCK) Inhibitors in In Vitro and In Vivo Models.

Authors:  Landon C Meekins; Noel Rosado-Adames; Rupalatha Maddala; Jiagang J Zhao; Ponugoti V Rao; Natalie A Afshari
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-12-01       Impact factor: 4.799

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.